Abstract
Cdc7 kinase has recently emerged as an attractive target for cancer therapy and low-molecular-weight inhibitors of Cdc7 kinase have been found to be effective in the inhibition of tumor growth in animal models. In this paper, we describe synthesis and structure-activity relationships of new 1H-pyrrolo[2,3-b]pyridine derivatives identified as inhibitors of Cdc7 kinase. Progress from (Z)-2-phenyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one (1) to [(Z)-2-(benzylamino)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1,3-thiazol-4(5H)-one] (42), a potent ATP mimetic inhibitor of Cdc7 kinase with IC(50) value of 7 nM, is also reported.
MeSH terms
-
Cell Cycle Proteins / antagonists & inhibitors*
-
Cell Cycle Proteins / chemistry
-
Cell Line
-
Humans
-
Models, Molecular
-
Molecular Conformation
-
Protein Kinase Inhibitors / analogs & derivatives
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / chemistry
-
Pyridines / chemical synthesis*
-
Pyridines / chemistry
-
Pyridines / pharmacology*
-
Structure-Activity Relationship
Substances
-
Cell Cycle Proteins
-
Protein Kinase Inhibitors
-
Pyridines
-
CDC7 protein, human
-
Protein Serine-Threonine Kinases